The $150M offering is a significant dilutive event that will pressure the stock near-term, but the positive Phase 2 data provides a fundamental catalyst that may support the stock. Monitor the final offering price and number of ADSs sold; the 60-day lock-up expiration could create additional selling pressure. The company expects cash runway into 2029, reducing near-term financing risk.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 11 $14.72entry
- T+1 · 3mo ago −7.74%α −8.00% · $13.58
- T+5 · 3mo ago −4.21%α −3.81% · $14.10
- T+20 · 2mo ago −7.95%α −6.89% · $13.55
- T+60 · 13d ago +34.51%α +35.00% · $19.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Silence Therapeutics is conducting a $150M underwritten public offering of ADSs, announced concurrently with positive Phase 2 SANRECO topline results for divesiran in polycythemia vera. The offering represents significant dilution (~27% of current market cap) but capitalizes on the stock's recent catalyst-driven appreciation to fund Phase 3 development. The net tangible book value was $27.7M ($0.59/ADS) as of June 30, 2026, and the offering will cause substantial dilution to new investors, though exact per-ADS dilution is not calculable as the offering price is not yet set.
Key Facts
- $150M public offering of ADSs (preliminary, subject to completion)
- Offering priced on August 10, 2026, the same day positive Phase 2 SANRECO topline results were announced
- Net tangible book value was $27.7M ($0.59/ADS) as of June 30, 2026
- Underwriters have a 30-day option to purchase additional ADSs
- Proceeds to fund continued clinical development and general corporate purposes
- Company expects cash runway into 2029 with net proceeds
- Lock-up agreements for officers and directors for 60 days after prospectus date
Financial Impact
$150M offering represents ~27% of $559M market cap; net tangible book value was $27.7M as of June 30, 2026; exact dilution per ADS not calculable as offering price is placeholder
Risk Factors
- Immediate and substantial dilution to existing shareholders
- Potential for further equity offerings given the $300M shelf and ATM facility
- Execution risk for Phase 3 trial initiation and regulatory approval
- Stock price may decline as new shares enter the market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-342633 |
| Document: 0001193125-26-342633-index-headers.html | 0001193125-26-342633 |
| Document: 0001193125-26-342633-index.html | 0001193125-26-342633 |
| Document: 0001193125-26-342633.txt | 0001193125-26-342633 |
Track record
15 reports on SLN
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers